🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

The Cigna Group CI SPXR3KPHARMA

Healthcare · Healthcare Plans · United States
https://www.thecignagroup.com
Company Profile ↓
$282.52
+0.58% 1Y
Mkt Cap$74.65B
P/E11.69
P/B1.75
Div. Yield2.27%
52W High$305.80
52W Low$240.32
Book Value$161.62
EPS (TTM)$24.17

Company Overview

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty pharmaceutical distribution, and clinical programs for whole-person health outcomes. The Cigna Healthcare segment comprises U.S. Healthcare and International Health, delivering comprehensive medical and coordinated solutions such as employer medical plans, individual and family plans, behavioral health, consumer health engagement, dental, pharmacy management, stop-loss insurance, global health care, and local health care solutions, as well as health care benefits for mobile individuals and employees of multinational organizations. The company offers other operations, including corporate-owned life insurance, reinsurance, and certain run-off and non-strategic businesses. The company distributes its products and services through brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 16.8%, reflecting efficient use of shareholder capital.

Consistent Profit Growth

Net profit has compounded at 15.6% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 27.3% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 11.7, below the sector median of 25.2.

Dividend Income

Offers a dividend yield of 2.27%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $273.85B (+11.3% YoY); net profit $5.96B.
  • Trailing 12 Months Year-on-year growth — revenue +6.7%, earnings +10.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 27.3%, profit CAGR 15.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:27.25%
1 Year:6.70%

Compounded Profit Growth

5 Years:15.61%
1 Year:10.20%

Stock Price Performance

1 Year:+0.58%
6 Months:+4.61%
3 Months:-2.40%
1 Month:+2.64%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 64% of range
$240.32 $305.80
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)51.63 · Neutral
Price Performance
1M+2.64%
3M-2.40%
6M+4.61%
1Y+0.58%
Valuation vs Sector

P/E of 11.69 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 27.3% over 5 years.
  • Profit CAGR of 15.6% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
11.69
Industry PE
25.17
Forward P/E
8.44
PEG Ratio
0.81
Book Value
$161.62
Price to Book
1.75
P/S
0.26
EV/EBITDA
7.80
Dividend Yield
2.27%

Growth (CAGR)

Revenue 5Y
27.25%
Profit 5Y
15.61%
Revenue (YoY)
6.70%
Earnings (YoY)
10.20%

Profitability & Returns

ROCE
8.03%
ROE
16.76%
ROA
4.46%
Profit Margin
2.27%
Op Margin
3.98%
Gross Margin
9.14%
EPS (Latest Qtr)
$6.29
EPS (TTM)
$24.17

Balance Sheet & Liquidity

Debt/Equity
0.74
Quick Ratio
0.69
Current Ratio
0.85
Debt
$31.88B
Total Assets
$157.08B
Current Assets
$47.81B
Working Capital
$-8.53B

Ownership

Promoter Holding
1.44%
Chg in Prom Hold
-0.00%
FII / Inst Holding
92.32%
Chg in FII Hold
-0.05%

Financial Snapshot

Enterprise Value
$74.65B
Total Revenue (TTM)
$282.38B
EBITDA
$12.76B
Free Cash Flow
$7.98B
Operating Cash Flow
$10.28B
Shares Outstanding
264.24M
Gross Margin
9.14%
Payout Ratio
25.39%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 CI The Cigna Group SPXR3KPHARMA 282.52 11.69 $74.65B 2.27% 8.03% 16.76% 27.25% 15.61%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue 10.43B10.37B10.37B10.63B11.41B11.48B11.46B14.30B37.95B38.82B38.56B38.24B38.47B39.27B40.95B40.97B43.13B44.29B44.01B45.48B45.28B46.52B48.59B49.05B57.26B60.52B63.69B65.50B67.18B69.75B68.49B71.67B
Operating Income ----1.31B1.16B1.13B-2.23B2.16B2.12B-2.06B2.64B2.11B1.96B2.15B2.29B2.19B2.37B2.14B2.02B2.22B2.24B2.26B2.41B2.58B1.97B2.31B2.58B2.36B2.68B
Net Income ---------------------------1.32B--1.65B1.66B
Diluted EPS 2.303.152.211.073.723.293.140.553.563.703.572.603.154.733.783.304.254.803.734.898.974.244.924.74-0.975.452.634.855.716.986.266.29

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 39.84B41.81B48.65B153.57B160.40B-179.36B194.10B246.15B273.85B
Cost of Revenue ------157.02B170.09B221.16B249.34B
Gross Profit ------22.34B24.01B24.99B24.51B
Operating Expenses ------15.05B16.64B16.55B16.36B
Operating Income 3.09B3.94B4.16B8.08B8.15B-7.29B7.37B8.44B8.15B
EBITDA ------12.56B9.99B9.48B11.96B
Interest Expense ------1.23B1.45B1.44B1.41B
Pretax Income ------8.40B5.51B5.27B7.78B
Tax Provision ------1.61B141.00M1.49B1.49B
Net Income 1.87B2.24B2.64B5.10B8.46B-6.70B5.16B3.43B5.96B
Diluted EPS 7.198.7710.5413.4422.96-21.3017.3912.1222.18

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --61.76B153.23B155.77B155.45B-143.88B152.76B155.88B157.92B
Current Assets -------30.12B37.35B48.87B47.81B
Cash & Equivalents 1.97B3.19B2.97B3.85B4.62B10.18B-5.92B7.82B7.55B7.68B
Inventory -------4.78B5.64B6.69B7.34B
Receivables -------17.22B17.72B24.23B28.77B
Total Liabilities --48.00B112.15B110.39B105.06B-99.13B106.41B114.64B116.05B
Current Liabilities --11.01B31.89B40.14B36.02B-41.23B48.72B57.98B56.34B
Long Term Debt -------28.10B28.16B28.94B30.87B
Total Debt -------31.09B30.93B31.97B31.46B
Total Equity 12.02B13.70B13.71B41.03B45.34B50.32B-44.67B46.22B41.03B41.71B
Shares Outstanding -------397.82M399.89M402.51M404.60M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 4.03B4.09B3.77B9.48B10.35B7.19B8.66B11.81B10.36B9.60B
Investing Cash Flow -2.57B-1.70B-26.38B-734.00M2.98B-3.61B3.10B-5.17B-2.10B-4.41B
Financing Cash Flow -225.00M-2.65B23.52B-7.19B-8.53B-8.21B-11.24B-4.29B-7.65B-6.42B
Capital Expenditure -461.00M-471.00M-528.00M-1.05B------
Free Cash Flow 3.56B3.62B3.24B8.44B------
Share Buybacks 139.00M2.73B342.00M1.99B4.04B7.74B7.61B2.28B7.03B3.62B

Ratios (Annual)

Figures in %.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ------12.5%12.4%10.2%9.0%
Operating Margin % 7.8%9.4%8.6%5.3%5.1%-4.1%3.8%3.4%3.0%
Net Margin % 4.7%5.4%5.4%3.3%5.3%-3.7%2.7%1.4%2.2%
ROE % 13.6%16.3%6.4%11.3%16.8%-15.0%11.2%8.4%14.3%
ROCE % -7.8%3.4%7.0%6.8%-7.1%7.1%8.6%8.0%

Shareholding Pattern

Insiders
1.44%
Institutions
92.32%
Public Float
93.67%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.87% 23.44M $6.54B
2 Vanguard Capital Management LLC 6.54% 17.28M $4.82B
3 State Street Corporation 4.80% 12.68M $3.54B
4 Dodge & Cox Inc. 4.61% 12.17M $3.40B
5 Massachusetts Financial Services Co. 3.95% 10.44M $2.91B
6 Sanders Capital, LLC 3.84% 10.14M $2.83B
7 FMR, LLC 3.03% 8.02M $2.24B
8 Geode Capital Management, LLC 2.37% 6.27M $1.75B
9 Vanguard Portfolio Management LLC 2.36% 6.23M $1.74B
10 GQG Partners LLC 2.24% 5.91M $1.65B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CI

Google News Fri, 04 Sep 2026

Cigna Corp (CI) Stock Price Today: $284.4 - Pluang

<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTE1vWV9KV0JqZWN3UjBUT2dyZ1dvY3IyT0NYZllDVXZYMDRvVjRJeDcxTWp4QzBvZjREeFdNeHFoLWZwNVVjQWk0THNIel93bG1CbkNRbXEtcw?oc=5" target="_blank">Cigna Corp (CI) Stock Price Today: $284.4</a>&nbs…

Google News Fri, 04 Sep 2026

Cigna Stock Price Forecast. Should You Buy CI? - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9wRlFLeHdQeHdYRWJSSWJpTEZoWnp2anYxNDRjcWsxazVqd2pSMFFHSUx1aXhGdEJ2OThZTFhZaEFsZ3d3Y1E?oc=5" target="_blank">Cigna Stock Price Forecast. Should You Buy CI?</a>&nbsp;&nbsp;<font colo…

Google News Sat, 05 Sep 2026

Cigna Group (CI) Launches New Benefits Offering Following Questions Over Whether Shares Are Fully Valued - simplywall.st

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQS01UaDNkMzBYeUZwRnp5Vm1JZS1talFEbi1UeDg4S2VwMkZHMmxLZDVmeWdPbl9UMHNncmV6OWZNV2JQeGZ0XzI5NlhCdUo2SU5EUHk1SHJSOEU1U2htOF9RUGhWUUFiMHZpandxLVlGWlhwS3pETEx5UnF4ZF9uVjNLZ3ZJWnpsTm83Qn…

Google News Mon, 13 Jul 2026

Why Cigna (CI) Stock Is Up Today - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOVlZpaHBFQzJoYW5yWjdCejI2bHpWS1liUnFFUlc4U0NaMEhILUZ1WU9aZFd3U3owZnlaeEVpVUFqSGM0NWxNOTFCbjB3Rnh1LUlxQTlEUlI2QW02dGRkWm1YMmJfOWlhQlY3SHZqeXBpWkY1V2s4ckRSYWVDazBBYkFLYURCTUVGN1dBdU…

Google News Mon, 07 Sep 2026

Price to sales forward of The Cigna Group – NYSE:CI - TradingView

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOR25VaVctSndSbVdFeVhxbGNVMnNmYUlQZS1oeUtFZnpMMGhid2h5YUUtZmU1bmF0MEJXa21lVHUtU1lwbm9kQkI5aGwzWjM0MlJEd1hpQWtHVHRPZldoSHI1Zl9leTB4STlob255clN1YVBpRzBNX2NSQXVSVDR5N1JORXhOSElRdE1BN1…

Google News hu, 03 Sep 2026

Cigna Group (NYSE: CI) gives CEO new stock options and restricted shares vesting from 2027 - Stock Titan

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNU2xtazdMTmxDaXBlX3JyR0tueHhWYmRLRzl3SjNNZEpEUWlhYUE3WncyOWVCOHZ3Wm9wQWZEb1ZuN1V3ZWktZzhZWGxfb1FfREc5dmx1SE9iZTV4Qi1SLXVndG14dlRRaWtnMWhvT00zaTF1aWVNSEZCenNhcG5sOW5nb2N6V2g4Rmp4TG…

CI — Frequently Asked Questions

What is the current share price of The Cigna Group (CI)?

As of 2026-09-07 16:24 PDT, The Cigna Group (CI) trades at $282.52 on NYSE. Its 52-week range is $240.32 to $305.80.

What is the market capitalisation of CI?

The Cigna Group (CI) has a market capitalisation of $74.65B on NYSE.

What is the P/E ratio of CI?

CI trades at a trailing price-to-earnings (P/E) ratio of 11.69. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.75.

Does CI pay a dividend?

The Cigna Group (CI) currently offers a dividend yield of 2.27%.

What is the return on equity (ROE) of CI?

CI has a return on equity (ROE) of 16.76%. Its return on capital employed (ROCE) is 8.03%.

Is CI a good stock to buy?

This page provides a data-driven analysis of The Cigna Group (CI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space